Loading
BC
Balchem Corp Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by MASON SCOTT C, was filed 05 Aug 2019.
Insider Decl.
456
Thresholds
n/a
Buy Volume
€277,660
2 ops. · all time
Sell Volume
€44M
75 ops. · all time
Who traded when
BuySaleDavid B. Fischer2 sales
Job Leonard van Gunsteren2 sales
Martin Luther Reid1 sale
Since the insiders bought
- +17.9%Entry US$86.31 · Close at T+365 US$101.78
- +10.6%Entry US$91.05 · Close at T+365 US$100.73
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Balchem Corp Buy (bullish), based on 4 analysts. Average price target: US$209.25.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 10,830 of 26,246 companies
56.0
score / 100
Value42
Quality70
FCF yld3.2%
Earn yld2.9%
EV/EBITDA22.0x
ROE13%
Gross mgn36%
Net mgn15%
Debt/EBITDA0.7x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$170.33
Analyst consensus
4 analystsBuy
US$165.00Target US$209.25(+23%)US$242.00
Income statement
RevenueUS$1B
Gross profitUS$370.6M36% margin
EBITDAUS$254.9M25% margin
Net incomeUS$154.8M15.1% margin
Valuation
PER (trailing)33.5x
PER (forward)27.2x
P/Book4.2x
Beta0.85
Balance sheet & cash
Market capUS$5.4B
Total debtUS$180.7M
Free Cash FlowUS$173.1M
Debt / Equity13%
Profitability & ownership
ROE12.8%
ROA8.2%
% insiders0.5%
% institutions93.4%
Last declaration on 13 February 2026
Declarations456 total
1,929 shares0Common StockSEC:0001140361-26-005516:1
2,247 shares0Common StockSEC:0001140361-26-005512:1
2,359 shares0Common StockSEC:0001140361-26-005542:1
1,345 shares0Common StockSEC:0001140361-26-005544:1
18,291 shares0Common StockSEC:0001140361-26-005536:1
1,664 shares0Common StockSEC:0001140361-26-005531:1
4,718 shares0Common StockSEC:0001140361-26-005510:1
2,247 shares0Common StockSEC:0001140361-26-005520:1
991 shares@ US$178.687.7% of flowCommon StockSEC:0001140361-26-005516:2
165 shares@ US$177.491.3% of flowCommon StockSEC:0001140361-26-005516:3
877 shares@ US$178.6830.7% of flowCommon StockSEC:0001140361-26-005512:2
181 shares@ US$177.496.3% of flowCommon StockSEC:0001140361-26-005512:3
1,085 shares@ US$178.6818.4% of flowCommon StockSEC:0001140361-26-005542:2
116 shares@ US$177.492.0% of flowCommon StockSEC:0001140361-26-005542:3
756 shares@ US$178.682.3% of flowCommon StockSEC:0001140361-26-005544:2
58 shares@ US$177.490.2% of flowCommon StockSEC:0001140361-26-005544:3
9,358 shares@ US$178.686.0% of flowCommon StockSEC:0001140361-26-005536:2
844 shares@ US$177.490.5% of flowCommon StockSEC:0001140361-26-005536:3
865 shares@ US$178.680.6% of flowCommon StockSEC:0001140361-26-005531:2
70 shares@ US$177.490.0% of flowCommon StockSEC:0001140361-26-005531:3
2,416 shares@ US$178.6813.1% of flowCommon StockSEC:0001140361-26-005510:2
302 shares@ US$177.491.6% of flowCommon StockSEC:0001140361-26-005510:3
1,151 shares@ US$178.6842.2% of flowCommon StockSEC:0001140361-26-005520:2
203 shares@ US$177.497.4% of flowCommon StockSEC:0001140361-26-005520:3
2,870 shares0Common StockSEC:0001140361-26-005520:0
25 of 456 declarations
About Balchem Corp
William A. Backus (CFO and Treasurer) made the largest sale at Balchem Corp: EUR 3,792,876 on March 13, 2017. Theodore L. Harris (Chairman, President & CEO) sold EUR 2,277,141 on February 21, 2024 and EUR 2,057,372 the next day. In all, 75 sales worth EUR 44,119,772 (median EUR 452,009), against 2 purchases worth EUR 277,660, so purchases are 3% of market trades.
The two purchases are Scott C. Mason's (Vice President), EUR 226,098 on August 5, 2019, and Daniel E. Knutson's (Director), EUR 51,562 on November 13, 2018.
Read moreShow less
This US chemicals and materials company, valued at USD 5.4 billion and 0.5% held by its insiders, has 456 filings published from February 26, 2016 to February 13, 2026, including 331 grants and 39 option exercises. William A. Backus (VP & Chief Accounting Officer) signed the most, 75, 16 of them sales, ahead of Theodore L. Harris (47). Yearly volume goes from 20 in 2020 to 81 in 2024. The last twelve months hold 57 filings, 5 of them sales and no purchase.
